PledPharma is an innovative, unique and integrated pharmaceutical drug development company, focusing on improving treatments for diseases with substantial unmet medical need.
Aladote® a first-in-class drug candidate, is being developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning. A proof of principle study has been successfully completed and the design of a pivotal Phase II/III study for US/EU regulatory submission is being finalized through ongoing regulatory interactions. Aladote® has been granted Orphan Drug Designation in the US.
Emcitate® a first-in-class drug candidate, is being developed for the treatment of MCT8 deficiency, a rare inborn error of thyroid hormone signaling. A first clinical trial has been concluded with significant and clinically relevant results. Emcitate® has been granted Orphan Drug Designation in the US and EU.
PledOx® a first-in-class drug candidate, is being developed to reduce nerve damage associated with chemotherapy. The Phase III POLAR program for the drug candidate PledOx® was prematurely stopped in Q2 2020. Results from POLAR program will determine if further development of PledOx® is warranted via strategic partnerships and is expected to be announced in Q4 2020.
PledPharma (STO: PLED) is listed on the Nasdaq Stockholm main market since October 31, 2019.
- protects the liver
Prevents acute liver failure in paracetamol poisoning.
- restores signaling
Restores thyroid hormone signaling in cells with defect MCT8 transporter.
- protects the peripheral nerves
Protection against the nerve damage that often occurs in connection with chemotherapy.